{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:42:45Z","timestamp":1787877765329,"version":"build-2784847793"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10557-025-07821-y","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T10:28:56Z","timestamp":1765362536000},"page":"1513-1534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology"],"prefix":"10.1007","volume":"40","author":[{"given":"Jathniel","family":"Panneflek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Barbarawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasitha","family":"Kakarlapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Barbarawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Lauzea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolo","family":"Meraz-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"7821_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6515\/ACS20151120A","volume":"32","author":"C-H Chen","year":"2016","unstructured":"Chen C-H. Critical questions about PARADIGM-HF and the future. Acta Cardiol Sin. 2016 [cited 2025 May 7];32:387\u201396. https:\/\/doi.org\/10.6515\/ACS20151120A.","journal-title":"Acta Cardiol Sin"},{"key":"7821_CR2","doi-asserted-by":"publisher","first-page":"e006570","DOI":"10.1161\/CIRCHEARTFAILURE.119.006570","volume":"13","author":"H Fish-Trotter","year":"2020","unstructured":"Fish-Trotter H, Ferguson JF, Patel N, Arora P, Allen NB, Bachmann KN, et al. Inflammation and Circulating natriuretic peptide levels. Circ Heart Fail. 2020 [cited 2025 May 7];13:e006570. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006570.","journal-title":"Circ Heart Fail"},{"key":"7821_CR3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/hrt.2005.074161","volume":"92","author":"SG Ray","year":"2006","unstructured":"Ray SG. Natriuretic peptides in heart valve disease. Heart. 2006 [cited 2025 May 8];92:1194\u20137. https:\/\/doi.org\/10.1136\/hrt.2005.074161.","journal-title":"Heart"},{"key":"7821_CR4","doi-asserted-by":"publisher","first-page":"e002423","DOI":"10.1161\/JAHA.115.002423","volume":"4","author":"R Kerkel\u00e4","year":"2015","unstructured":"Kerkel\u00e4 R, Ulvila J, Magga J. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2015;4:e002423. https:\/\/doi.org\/10.1161\/JAHA.115.002423. [cited 2025 May 8];.","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"7821_CR5","doi-asserted-by":"publisher","unstructured":"Zografos TA, Athens Euroclinic DG, Athens, Euroclinic. Department of Cardiology, 9 Athanasiadou Street, Athens 11521, Greece. E: dkatritsis@euroclinic.gr. Natriuretic Peptides as Predictors of Atrial Fibrillation Recurrences Following Electrical Cardioversion. Arrhythmia Electrophysiol Rev. 2013 [cited 2025 May 8];2:109. https:\/\/doi.org\/10.15420\/aer.2013.2.2.109","DOI":"10.15420\/aer.2013.2.2.109"},{"key":"7821_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jchf.2019.05.012","volume":"7","author":"SH Reginauld","year":"2019","unstructured":"Reginauld SH, Cannone V, Iyer S, Scott C, Bailey K, Schaefer J, et al. Differential regulation of ANP and BNP in acute decompensated heart failure: deficiency of ANP. JACC Heart Fail. 2019 [cited 2025 May 7];7:891\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2019.05.012.","journal-title":"JACC Heart Fail"},{"key":"7821_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1113\/jphysiol.2007.144253","volume":"586","author":"RA Rose","year":"2008","unstructured":"Rose RA, Giles WR. Natriuretic peptide C receptor signalling in the heart and vasculature. J Physiol. 2008;586:353\u201366. https:\/\/doi.org\/10.1113\/jphysiol.2007.144253. cited 2025 May 7.","journal-title":"J Physiol"},{"key":"7821_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacc.2004.10.067","volume":"45","author":"T Soeki","year":"2005","unstructured":"Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, et al. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol. 2005;45:608\u201316. [cited 2025 May 7]. https:\/\/doi.org\/10.1016\/j.jacc.2004.10.067.","journal-title":"J Am Coll Cardiol"},{"key":"7821_CR9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1111\/febs.13701","volume":"283","author":"A Sen","year":"2016","unstructured":"Sen A, Kumar P, Garg R, Lindsey SH, Katakam PVG, Bloodworth M, et al. Transforming growth factor \u03b21 antagonizes the transcription, expression and vascular signaling of Guanylyl cyclase\/natriuretic peptide receptor A \u2013 role of \u03b4 EF 1. FEBS J. 2016;283:1767\u201381. https:\/\/doi.org\/10.1111\/febs.13701. [cited 2025 May 7].","journal-title":"FEBS J"},{"key":"7821_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/CIRCRESAHA.107.157677","volume":"102","author":"P Li","year":"2008","unstructured":"Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, et al. Atrial natriuretic peptide inhibits transforming growth factor \u03b2\u2013Induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res. 2008;102:185\u201392. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.157677. [cited 2025 May 7].","journal-title":"Circ Res"},{"key":"7821_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000495946","volume":"141","author":"J Savoj","year":"2019","unstructured":"Savoj J, Becerra B, Kim JK, Fusaro M, Gallieni M, Lombardo D, et al. Utility of cardiac biomarkers in the setting of kidney disease. Nephron. 2019;141:227\u201335. https:\/\/doi.org\/10.1159\/000495946. [cited 2025 May 7].","journal-title":"Nephron"},{"key":"7821_CR12","doi-asserted-by":"publisher","first-page":"100691","DOI":"10.1016\/j.jacadv.2023.100691","volume":"2","author":"M Volpe","year":"2023","unstructured":"Volpe M, Gallo G, Rubattu S. BNP\/NT-proBNP levels are sensitive markers of impaired prognosis in patients without heart failure. JACC Adv. 2023;2:100691. [cited 2025 May 7]. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100691.","journal-title":"JACC Adv"},{"key":"7821_CR13","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.3390\/jcm12093101","volume":"12","author":"SJ Maurer","year":"2023","unstructured":"Maurer SJ, Habdank V, H\u00f6rer J, Ewert P, Tutarel O. NT-proBNP is a predictor of mortality in adults with pulmonary arterial hypertension associated with congenital heart disease. J Clin Med. 2023;12:3101. https:\/\/doi.org\/10.3390\/jcm12093101. [cited 2025 May 7];.","journal-title":"J Clin Med"},{"key":"7821_CR14","doi-asserted-by":"publisher","unstructured":"Adamska-We\u0142nicka A, We\u0142nicki M, Mamcarz A, Gellert R. Chronic Kidney Disease and Heart Failure\u2013Everyday Diagnostic Challenges. Diagnostics. 2021 [cited 2025 May 7];11:2164. https:\/\/doi.org\/10.3390\/diagnostics11112164","DOI":"10.3390\/diagnostics11112164"},{"key":"7821_CR15","doi-asserted-by":"publisher","first-page":"e70044","DOI":"10.1002\/clc.70044","volume":"47","author":"RK Bahniwal","year":"2024","unstructured":"Bahniwal RK, Sadr N, Schinderle C, Avila CJ, Sill J, Qayyum R. Obesity paradox and the effect of NT-proBNP on All\u2010Cause and Cause\u2010Specific mortality. Clin Cardiol. 2024;47:e70044. https:\/\/doi.org\/10.1002\/clc.70044. [cited 2025 May 7].","journal-title":"Clin Cardiol"},{"key":"7821_CR16","doi-asserted-by":"publisher","first-page":"e018689","DOI":"10.1161\/JAHA.120.018689","volume":"10","author":"V Parcha","year":"2021","unstructured":"Parcha V, Patel N, Kalra R, Suri SS, Arora G, Wang TJ, et al. Obesity and serial NT-proBNP levels in guided medical therapy for heart failure with reduced ejection fraction: insights from the GUIDE\u2010IT trial. J Am Heart Assoc. 2021;10:e018689. https:\/\/doi.org\/10.1161\/JAHA.120.018689. [cited 2025 May 7].","journal-title":"J Am Heart Assoc"},{"key":"7821_CR17","doi-asserted-by":"publisher","unstructured":"Brutsaert DL, Andries LJ. The endocardial endothelium. Am J physiol-Heart circ physiol. Volume 263. American Physiological Society; 1992. pp. H985\u20131002. [cited 2025 May 22]. https:\/\/doi.org\/10.1152\/ajpheart.1992.263.4.H985.","DOI":"10.1152\/ajpheart.1992.263.4.H985"},{"key":"7821_CR18","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.3390\/ijms21207462","volume":"21","author":"MS Sadek","year":"2020","unstructured":"Sadek MS, Cachorro E, El-Armouche A, K\u00e4mmerer S. Therapeutic implications for PDE2 and cGMP\/cAMP mediated crosstalk in cardiovascular diseases. Int J Mol Sci. 2020;21:7462. https:\/\/doi.org\/10.3390\/ijms21207462. [cited 2025 May 22].","journal-title":"Int J Mol Sci"},{"key":"7821_CR19","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1172\/JCI37430","volume":"119","author":"M Kuhn","year":"2009","unstructured":"Kuhn M, V\u00f6lker K, Schwarz K, Carbajo-Lozoya J, Fl\u00f6gel U, Jacoby C, et al. The natriuretic peptide\/guanylyl cyclase\u2013A system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest. 2009;119:2019\u201330. https:\/\/doi.org\/10.1172\/JCI37430. [cited 2025 May 10];.","journal-title":"J Clin Invest"},{"key":"7821_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1476-5381.2012.01827.x","volume":"166","author":"M Kuhn","year":"2012","unstructured":"Kuhn M. Endothelial actions of atrial and B-type natriuretic peptides. Br J Pharmacol. 2012;166:522\u201331. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01827.x. [cited 2025 May 22].","journal-title":"Br J Pharmacol"},{"key":"7821_CR21","doi-asserted-by":"publisher","first-page":"e007208","DOI":"10.1161\/CIRCHEARTFAILURE.120.007208","volume":"13","author":"V Ramakrishnan","year":"2020","unstructured":"Ramakrishnan V, Burnett JC. Natriuretic Peptides, Inflammation, and sounding the alarm. Circ Heart Fail. 2020;13:e007208. [cited 2025 May 22]. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007208.","journal-title":"Circ Heart Fail"},{"key":"7821_CR22","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Rivas G, Lozano O, Bernal-Ram\u00edrez J, Silva-Platas C, Salazar-Ram\u00edrez F, M\u00e9ndez-Fern\u00e1ndez A, et al. Cannabidiol prevents heart failure dysfunction and remodeling through preservation of mitochondrial function and calcium handling. JACC Basic Transl Sci. 2025; S2452302X24004595. https:\/\/doi.org\/10.1016\/j.jacbts.2024.12.009. [cited 2025 May 22].","DOI":"10.1016\/j.jacbts.2024.12.009"},{"key":"7821_CR23","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","volume":"110","author":"UC Sharma","year":"2004","unstructured":"Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, et al. Galectin-3 marks activated macrophages in Failure-Prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121\u20138. https:\/\/doi.org\/10.1161\/01.CIR.0000147181.65298.4D. [cited 2018 Dec 10].","journal-title":"Circulation"},{"key":"7821_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.immuni.2017.08.009","volume":"47","author":"GS Hotamisligil","year":"2017","unstructured":"Hotamisligil GS. Foundations of immunometabolism and implications for metabolic health and disease. Immunity. 2017;47:406\u201320. https:\/\/doi.org\/10.1016\/j.immuni.2017.08.009. cited 2025 May 22.","journal-title":"Immunity"},{"key":"7821_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.ijcard.2016.11.054","volume":"228","author":"K Hirakawa","year":"2017","unstructured":"Hirakawa K, Yamamuro M, Uemura T, Takashio S, Kaikita K, Utsunomiya D, et al. Correlation between microvascular dysfunction and B-type natriuretic peptide levels in non-ischemic heart failure patients with cardiac fibrosis. Int J Cardiol. 2017;228:881\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.054. cited 2025 May 22.","journal-title":"Int J Cardiol"},{"key":"7821_CR26","doi-asserted-by":"publisher","first-page":"e027618","DOI":"10.1161\/JAHA.122.027618","volume":"11","author":"EL Matthia","year":"2022","unstructured":"Matthia EL, Setteducato ML, Elzeneini M, Vernace N, Salerno M, Kramer CM, et al. Circulating biomarkers in hypertrophic cardiomyopathy. J Am Heart Assoc. 2022;11:e027618. [cited 2025 May 22]. https:\/\/doi.org\/10.1161\/JAHA.122.027618.","journal-title":"J Am Heart Assoc"},{"key":"7821_CR27","doi-asserted-by":"publisher","first-page":"1182530","DOI":"10.3389\/fcvm.2023.1182530","volume":"10","author":"PN Cavalcante","year":"2023","unstructured":"Cavalcante PN, Kanhouche G, Rosa VEE, Campos CM, Lopes MP, Lopes MAAADM, et al. B-type natriuretic peptide and N-terminal Pro-B-type natriuretic peptide in severe aortic stenosis: a comprehensive literature review. Front Cardiovasc Med. 2023;10:1182530. [cited 2025 May 22]. https:\/\/doi.org\/10.3389\/fcvm.2023.1182530.","journal-title":"Front Cardiovasc Med"},{"key":"7821_CR28","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.3390\/jcm14103267","volume":"14","author":"PO Odutola","year":"2025","unstructured":"Odutola PO, Olarewaju A, Shah P. Effectiveness of atrial natriuretic peptide in the treatment of critically ill patients: A systematic review and Meta-Analysis. J Clin Med. 2025;14:3267. https:\/\/doi.org\/10.3390\/jcm14103267. [cited 2025 May 22].","journal-title":"J Clin Med"},{"key":"7821_CR29","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303. [cited 2025 Feb 19].","journal-title":"N Engl J Med"},{"key":"7821_CR30","doi-asserted-by":"publisher","first-page":"107863","DOI":"10.1016\/j.pharmthera.2021.107863","volume":"227","author":"K Kuwahara","year":"2021","unstructured":"Kuwahara K. The natriuretic peptide system in heart failure: diagnostic and therapeutic implications. Pharmacol Ther. 2021;227:107863. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107863. [cited 2025 May 7].","journal-title":"Pharmacol Ther"},{"key":"7821_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/cvr\/cvac144","volume":"119","author":"T Liu","year":"2023","unstructured":"Liu T, Meng Z, Liu J, Li J, Zhang Y, Deng Z, et al. Group 2 innate lymphoid cells protect mouse heart from myocardial infarction injury via Interleukin 5, eosinophils, and dendritic cells. Cardiovasc Res. 2023;119:1046\u201361. https:\/\/doi.org\/10.1093\/cvr\/cvac144. [cited 2025 May 7].","journal-title":"Cardiovasc Res"},{"key":"7821_CR32","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jacc.2013.04.073","volume":"62","author":"SS Gottlieb","year":"2013","unstructured":"Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, et al. Effects of nesiritide and predictors of urine output in acute decompensated heart failure. J Am Coll Cardiol. 2013;62:1177\u201383. https:\/\/doi.org\/10.1016\/j.jacc.2013.04.073. [cited 2025 May 20].","journal-title":"J Am Coll Cardiol"},{"key":"7821_CR33","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.121.056657","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer M, Zannad F, Anker SD. Heart failure and a preserved ejection fraction: A Side-by-Side examination of the PARAGON-HF and EMPEROR-Preserved trials. Circulation. 2021;144:1193\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056657. [cited 2025 May 8].","journal-title":"Circulation"},{"key":"7821_CR34","doi-asserted-by":"publisher","first-page":"754499","DOI":"10.3389\/fcvm.2021.754499","volume":"8","author":"D Pascual-Figal","year":"2021","unstructured":"Pascual-Figal D, Bay\u00e9s-Genis A, Beltr\u00e1n-Troncoso P, Caravaca-P\u00e9rez P, Conde-Martel A, Crespo-Leiro MG, et al. Sacubitril-Valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection Fraction. A review. Front Cardiovasc Med. 2021;8:754499. https:\/\/doi.org\/10.3389\/fcvm.2021.754499. [cited 2025 May 8].","journal-title":"Front Cardiovasc Med"},{"key":"7821_CR35","doi-asserted-by":"publisher","first-page":"bvaa052","DOI":"10.1210\/jendso\/bvaa052","volume":"4","author":"S Vinnakota","year":"2020","unstructured":"Vinnakota S, Chen HH. The importance of natriuretic peptides in cardiometabolic diseases. J Endocr Soc. 2020;4:bvaa052. https:\/\/doi.org\/10.1210\/jendso\/bvaa052. [cited 2025 May 8].","journal-title":"J Endocr Soc"},{"key":"7821_CR36","doi-asserted-by":"publisher","unstructured":"Packer M, O\u2019Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017 [cited 2025 May 11];376:1956\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1601895","DOI":"10.1056\/NEJMoa1601895"},{"key":"7821_CR37","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/eurheartj\/ehu484","volume":"36","author":"SD Anker","year":"2015","unstructured":"Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015;36:715\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehu484. [cited 2025 May 8].","journal-title":"Eur Heart J"},{"key":"7821_CR38","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038. [cited 2025 May 8].","journal-title":"N Engl J Med"},{"key":"7821_CR39","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, De Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286. [cited 2025 May 8].","journal-title":"N Engl J Med"},{"key":"7821_CR40","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin\u2013Neprilysin Inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655. [cited 2025 May 8].","journal-title":"N Engl J Med"},{"key":"7821_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1751-7133.2008.00045.x","volume":"15","author":"M Tapolyai","year":"2009","unstructured":"Tapolyai M, Uysal A, Maeweathers G, Bahta E, Dossabhoy NR. B-Type natriuretic Peptide\u2013Directed ultrafiltration improves care in acutely hospitalized Dialysis patients. Congest Heart Fail. 2009;15:131\u20135. https:\/\/doi.org\/10.1111\/j.1751-7133.2008.00045.x. [cited 2025 May 8];.","journal-title":"Congest Heart Fail"},{"key":"7821_CR42","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jchf.2025.02.022","volume":"13","author":"DDSP Belfort","year":"2025","unstructured":"Belfort DDSP, Bocchi EA, Cafezeiro CRF, Wanderley MRB, Salemi VMC, Rocon C, et al. Carvedilol as single therapy for heart failure with improved ejection fraction. JACC Heart Fail. 2025;13:1041\u20134. https:\/\/doi.org\/10.1016\/j.jchf.2025.02.022. [cited 2025 June 17].","journal-title":"JACC Heart Fail"},{"key":"7821_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1100171","volume":"365","author":"CM O\u2019Connor","year":"2011","unstructured":"O\u2019Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1100171. [cited 2025 May 8].","journal-title":"N Engl J Med"},{"key":"7821_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","volume":"51","author":"DO Okonko","year":"2008","unstructured":"Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol. 2008;51:103\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.036. [cited 2025 May 8].","journal-title":"J Am Coll Cardiol"},{"key":"7821_CR45","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2022.08.012","volume":"10","author":"MR Zile","year":"2022","unstructured":"Zile MR, Mehra MR, Ducharme A, Sears SF, Desai AS, Maisel A, et al. Hemodynamically-Guided management of heart failure across the ejection fraction spectrum. JACC Heart Fail. 2022;10:931\u201344. https:\/\/doi.org\/10.1016\/j.jchf.2022.08.012. [cited 2025 May 8];.","journal-title":"JACC Heart Fail"},{"key":"7821_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1136\/bmjebm-2019-111208","volume":"25","author":"J McLellan","year":"2020","unstructured":"McLellan J, Bankhead CR, Oke JL, Hobbs FDR, Taylor CJ, Perera R. Natriuretic peptide-guided treatment for heart failure: a systematic review and meta-analysis. BMJ Evid-Based Med. 2020;25:33\u20137. https:\/\/doi.org\/10.1136\/bmjebm-2019-111208. [cited 2025 May 8].","journal-title":"BMJ Evid-Based Med"},{"key":"7821_CR47","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.cardfail.2012.05.005","volume":"18","author":"HK Gaggin","year":"2012","unstructured":"Gaggin HK, Mohammed AA, Bhardwaj A, Rehman SU, Gregory SA, Weiner RB, et al. Heart failure outcomes and benefits of NT-proBNP-Guided management in the elderly: results from the Prospective, randomized probnp outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail. 2012;18:626\u201334. https:\/\/doi.org\/10.1016\/j.cardfail.2012.05.005. [cited 2025 May 8];.","journal-title":"J Card Fail"},{"key":"7821_CR48","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1186\/cc10119","volume":"15","author":"G Coutance","year":"2011","unstructured":"Coutance G, Cauderlier E, Ehtisham J, Hamon M, Hamon M. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis. Crit Care. 2011;15:R103. https:\/\/doi.org\/10.1186\/cc10119. [cited 2025 May 8].","journal-title":"Crit Care"},{"key":"7821_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ahj.2022.05.006","volume":"250","author":"PM Hendriks","year":"2022","unstructured":"Hendriks PM, Van De Groep LD, Veen KM, Van Thor MCJ, Meertens S, Boersma E, et al. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis. Am Heart J. 2022;250:34\u201344. https:\/\/doi.org\/10.1016\/j.ahj.2022.05.006. [cited 2025 May 8].","journal-title":"Am Heart J"},{"key":"7821_CR50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","volume":"102","author":"N Nagaya","year":"2000","unstructured":"Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865\u201370. https:\/\/doi.org\/10.1161\/01.CIR.102.8.865. [cited 2025 May 22];.","journal-title":"Circulation"},{"key":"7821_CR51","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1378\/chest.107.5.1193","volume":"107","author":"M Oswald-Mammosser","year":"1995","unstructured":"Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, et al. Prognostic factors in COPD patients receiving Long-term oxygen therapy. Chest. 1995;107:1193\u20138. https:\/\/doi.org\/10.1378\/chest.107.5.1193. [cited 2025 May 22];.","journal-title":"Chest"},{"key":"7821_CR52","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.rmed.2007.06.027","volume":"101","author":"J Suntharalingam","year":"2007","unstructured":"Suntharalingam J, Goldsmith K, Toshner M, Doughty N, Sheares KK, Hughes R, et al. Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respir Med. 2007;101:2254\u201362. https:\/\/doi.org\/10.1016\/j.rmed.2007.06.027. [cited 2025 May 8].","journal-title":"Respir Med"},{"key":"7821_CR53","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/eurjhf\/hfq169","volume":"12","author":"H Persson","year":"2010","unstructured":"Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlstr\u00f6m U. Improved Pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP guided management of heart Failure \u2013 SIGNAL\u2010HF (Swedish intervention study \u2013 Guidelines and NT\u2010proBNP analysis in heart Failure). Eur J Heart Fail. 2010;12:1300\u20138. https:\/\/doi.org\/10.1093\/eurjhf\/hfq169. [cited 2025 May 8];.","journal-title":"Eur J Heart Fail"},{"key":"7821_CR54","doi-asserted-by":"publisher","unstructured":"Pandompatam G, Kashani K, Vallabhajosyula S. The role of natriuretic peptides in the management, outcomes and prognosis of sepsis and septic shock. Rev Bras Ter Intensiva. 2019 [cited 2025 May 8];31. https:\/\/doi.org\/10.5935\/0103-507X.20190060","DOI":"10.5935\/0103-507X.20190060"},{"key":"7821_CR55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jointm.2021.11.004","volume":"2","author":"F Boissier","year":"2022","unstructured":"Boissier F, Aissaoui N. Septic cardiomyopathy: diagnosis and management. J Intensive Med. 2022;2:8\u201316. https:\/\/doi.org\/10.1016\/j.jointm.2021.11.004. [cited 2025 May 22].","journal-title":"J Intensive Med"},{"key":"7821_CR56","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40560-015-0112-5","volume":"3","author":"R Sato","year":"2015","unstructured":"Sato R, Nasu M. A review of sepsis-induced cardiomyopathy. J Intensive Care. 2015;3:48. https:\/\/doi.org\/10.1186\/s40560-015-0112-5. [cited 2025 May 22].","journal-title":"J Intensive Care"},{"key":"7821_CR57","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4103\/0970-9185.194778","volume":"32","author":"GF Elbaradey","year":"2016","unstructured":"Elbaradey GF, Elshmaa NS, Hodeib H. The effect of atrial natriuretic peptide infusion on intestinal injury in septic shock. J Anaesthesiol Clin Pharmacol. 2016;32:470\u20135. https:\/\/doi.org\/10.4103\/0970-9185.194778.","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"7821_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12882-020-1701-7","volume":"21","author":"K Saito","year":"2020","unstructured":"Saito K, Uchino S, Fujii T, Saito S, Takinami M, Uezono S. Effect of low-dose atrial natriuretic peptide in critically ill patients with acute kidney injury: a retrospective, single-center study with propensity-score matching. BMC Nephrol. 2020;21:31. https:\/\/doi.org\/10.1186\/s12882-020-1701-7. [cited 2025 May 8];.","journal-title":"BMC Nephrol"},{"key":"7821_CR59","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.chest.2018.06.025","volume":"154","author":"PJ Mazzone","year":"2018","unstructured":"Mazzone PJ, Silvestri GA, Patel S, Kanne JP, Kinsinger LS, Wiener RS, et al. Response Chest. 2018;154:716\u20137. https:\/\/doi.org\/10.1016\/j.chest.2018.06.025. [cited 2025 May 22];.","journal-title":"Response Chest"},{"key":"7821_CR60","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/cvr\/cvt026","volume":"98","author":"E Pol\u00e1kov\u00e1","year":"2013","unstructured":"Pol\u00e1kov\u00e1 E, Sobie EA. Alterations in T-tubule and dyad structure in heart disease: challenges and opportunities for computational analyses. Cardiovasc Res. 2013;98:233\u20139. https:\/\/doi.org\/10.1093\/cvr\/cvt026. [cited 2025 May 22].","journal-title":"Cardiovasc Res"},{"key":"7821_CR61","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4161\/viru.26907","volume":"5","author":"M Singer","year":"2014","unstructured":"Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5:66\u201372. https:\/\/doi.org\/10.4161\/viru.26907. [cited 2025 May 22].","journal-title":"Virulence"},{"key":"7821_CR62","doi-asserted-by":"publisher","unstructured":"Cellier L, Tamareille S, Kalakech H, Guillou S, Lenaers G, Prunier F et al. Remote Ischemic Conditioning Influences Mitochondrial Dynamics. Shock. 2016 [cited 2025 May 22];45:192\u20137. https:\/\/doi.org\/10.1097\/SHK.0000000000000500","DOI":"10.1097\/SHK.0000000000000500"},{"key":"7821_CR63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/24748706.2017.1329959","volume":"1","author":"B Redfors","year":"2017","unstructured":"Redfors B, Furer A, Lindman BR, Burkhoff D, Marquis-Gravel G, Francese DP, et al. Biomarkers in aortic stenosis: A systematic review. Struct Heart. 2017;1:18\u201330. https:\/\/doi.org\/10.1080\/24748706.2017.1329959. [cited 2025 May 8];.","journal-title":"Struct Heart"},{"key":"7821_CR64","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamacardio.2020.2614","volume":"5","author":"JM O\u2019Leary","year":"2020","unstructured":"O\u2019Leary JM, Clavel M-A, Chen S, Goel K, O\u2019Neill B, Elmariah S, et al. Association of natriuretic peptide levels after transcatheter aortic valve replacement with subsequent clinical outcomes. JAMA Cardiol. 2020;5:1113. https:\/\/doi.org\/10.1001\/jamacardio.2020.2614. [cited 2025 May 8];.","journal-title":"JAMA Cardiol"},{"key":"7821_CR65","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.2459\/JCM.0000000000001230","volume":"23","author":"H Lehtola","year":"2022","unstructured":"Lehtola H, Piuhola J, Niemel\u00e4 M, Tauriainen T, Junttila J, M\u00e4kikallio T, et al. B-type natriuretic peptide ability to predict mortality after transcatheter aortic valve replacement. J Cardiovasc Med. 2022;23:e18\u201320. https:\/\/doi.org\/10.2459\/JCM.0000000000001230. [cited 2025 May 8].","journal-title":"J Cardiovasc Med"},{"key":"7821_CR66","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jacc.2016.06.047","volume":"68","author":"M-A Clavel","year":"2016","unstructured":"Clavel M-A, Tribouilloy C, Vanoverschelde J-L, Pizarro R, Suri RM, Szymanski C, et al. Association of B-Type natriuretic peptide with survival in patients with degenerative mitral regurgitation. J Am Coll Cardiol. 2016;68:1297\u2013307. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.047. [cited 2025 May 8].","journal-title":"J Am Coll Cardiol"},{"key":"7821_CR67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/1995-705X.182648","volume":"17","author":"E Abdel Fattah","year":"2016","unstructured":"Abdel Fattah E, Girgis HA, El Khashab K, Ashour Z, Ezzat G. B-type natriuretic peptide as an index of symptoms and severity of chronic rheumatic mitral regurgitation. Heart Views. 2016;17:7. https:\/\/doi.org\/10.4103\/1995-705X.182648. [cited 2025 May 8];.","journal-title":"Heart Views"},{"key":"7821_CR68","doi-asserted-by":"publisher","unstructured":"Coisne A, Lancellotti P, C\u00f4t\u00e9 N, Ternacle J, Hecht S, Grapsa J, et al. Blood biomarkers in left-sided valvular heart disease. Eur Heart J. 2025 [cited 2025 May 8];ehaf232. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf232.","DOI":"10.1093\/eurheartj\/ehaf232"},{"key":"7821_CR69","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/cpt.3417","volume":"117","author":"DS Lin","year":"2025","unstructured":"Lin DS, Chao Y, Chuang S, Lee J, Lin T, Lin L, et al. Effects of Sacubitril\/Valsartan on survival in patients with heart failure and significant valvular heart disease. Clin Pharmacol Ther. 2025;117:143\u201352. https:\/\/doi.org\/10.1002\/cpt.3417. [cited 2025 Feb 19].","journal-title":"Clin Pharmacol Ther"},{"key":"7821_CR70","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.rec.2013.06.020","volume":"67","author":"N Farr\u00e9","year":"2014","unstructured":"Farr\u00e9 N, G\u00f3mez M, Molina L, Cladellas M, Bl\u00e9 M, Roqueta C, et al. Prognostic value of NT-proBNP and an adapted Monin score in patients with asymptomatic aortic stenosis. Rev Esp Cardiol Engl Ed. 2014;67:52\u20137. https:\/\/doi.org\/10.1016\/j.rec.2013.06.020. [cited 2025 May 8];.","journal-title":"Rev Esp Cardiol Engl Ed"},{"key":"7821_CR71","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1161\/CIR.0000000000000923","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: A report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation. 2021;143:e72\u2013227. https:\/\/doi.org\/10.1161\/CIR.0000000000000923. [cited 2025 May 14];.","journal-title":"Circulation"},{"key":"7821_CR72","doi-asserted-by":"publisher","first-page":"e095105","DOI":"10.1136\/bmjopen-2024-095105","volume":"15","author":"H Kitahara","year":"2025","unstructured":"Kitahara H, Okita S, Sugawara T, Yaginuma H, Goto H, Yamamoto H, et al. Evaluation of the efficacy of angiotensin receptor\u2013neprilysin inhibitor in patients with aortic stenosis undergoing transcatheter aortic valve implantation: protocol for a randomised, open-label, controlled study. BMJ Open. 2025;15:e095105. https:\/\/doi.org\/10.1136\/bmjopen-2024-095105. [cited 2025 May 8];.","journal-title":"BMJ Open"},{"key":"7821_CR73","doi-asserted-by":"publisher","unstructured":"Hatab I, Kneihsl M, Arnold M, Pokorny T, Westphal LP, Bicciato G et al. Role of NT-proBNP for atrial fibrillation detection after ischemic stroke: A Time-Dependent relationship. Stroke. 2025 [cited 2025 May 8];STROKEAHA.124.049249. https:\/\/doi.org\/10.1161\/STROKEAHA.124.049249","DOI":"10.1161\/STROKEAHA.124.049249"},{"key":"7821_CR74","doi-asserted-by":"publisher","unstructured":"Diakantonis A, Verras C, Bezati S, Bistola V, Ventoulis I, Velliou M et al. Predictive Value of N-Terminal Pro B-Type Natriuretic Peptide for Short-Term Outcome of Cardioversion in Patients with First-Diagnosed or Paroxysmal Atrial Fibrillation Presenting to the Emergency Department. Biomedicines. 2024 [cited 2025 May 22];12:2895. https:\/\/doi.org\/10.3390\/biomedicines12122895","DOI":"10.3390\/biomedicines12122895"},{"key":"7821_CR75","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1253\/circj.72.921","volume":"72","author":"H M\u00f6llmann","year":"2008","unstructured":"M\u00f6llmann H, Weber M, Els\u00e4sser A, Nef H, Dill T, Rixe J, et al. NT-ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J. 2008;72:921\u20135. https:\/\/doi.org\/10.1253\/circj.72.921. [cited 2025 May 22].","journal-title":"Circ J"},{"key":"7821_CR76","doi-asserted-by":"publisher","unstructured":"Habibi Z, Verhaert DVM, Betz K, Hermans BJM, Winters J, Philippens SAM et al. Association of atrial fibrillation burden and clinical profile with blood biomarkers: Results from the ISOLATION Ablation Cohort. Heart Rhythm O2. 2025 [cited 2025 May 22];6:661\u201370. https:\/\/doi.org\/10.1016\/j.hroo.2025.02.017","DOI":"10.1016\/j.hroo.2025.02.017"},{"key":"7821_CR77","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00392-019-01513-y","volume":"109","author":"BT Santema","year":"2020","unstructured":"Santema BT, Chan MMY, Tromp J, Dokter M, Van Der Wal HH, Emmens JE, et al. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clin Res Cardiol. 2020;109:331\u20138. https:\/\/doi.org\/10.1007\/s00392-019-01513-y. [cited 2025 May 22].","journal-title":"Clin Res Cardiol"},{"key":"7821_CR78","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41598-022-05769-9","volume":"12","author":"PB Meyre","year":"2022","unstructured":"Meyre PB, Aeschbacher S, Blum S, Voellmin G, Kastner PM, Hennings E, et al. Biomarkers associated with rhythm status after cardioversion in patients with atrial fibrillation. Sci Rep. 2022;12:1680. https:\/\/doi.org\/10.1038\/s41598-022-05769-9. [cited 2025 May 22];.","journal-title":"Sci Rep"},{"key":"7821_CR79","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000081009","volume":"102","author":"CS Vinch","year":"2004","unstructured":"Vinch CS, Rashkin J, Logsetty G, Tighe DA, Hill JC, Meyer TE, et al. Brain natriuretic peptide levels fall rapidly after cardioversion of atrial fibrillation to sinus rhythm. Cardiology. 2004;102:188\u201393. https:\/\/doi.org\/10.1159\/000081009. [cited 2025 May 22].","journal-title":"Cardiology"},{"key":"7821_CR80","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/eurheartj\/ehaf034","volume":"46","author":"L Anderson","year":"2025","unstructured":"Anderson L, Bayes-Genis A, Bodeg\u00e5rd J, Mullin K, Gustafsson S, Rosano GMC, et al. Suspected de Novo heart failure in outpatient care: the REVOLUTION HF study. Eur Heart J. 2025;46:1493\u2013503. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf034. [cited 2025 May 8].","journal-title":"Eur Heart J"},{"key":"7821_CR81","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1113\/EP092068","volume":"109","author":"R Sarzani","year":"2024","unstructured":"Sarzani R, Landolfo M, Giulietti F, Spannella F. Osteocrin\/musclin and the natriuretic peptides system: A novel focus in metabolism and cardiovascular prevention. Exp Physiol. 2024;109:1251\u20132. https:\/\/doi.org\/10.1113\/EP092068. [cited 2025 May 8].","journal-title":"Exp Physiol"},{"key":"7821_CR82","doi-asserted-by":"publisher","first-page":"14415","DOI":"10.3390\/ijms232214415","volume":"23","author":"R Sarzani","year":"2022","unstructured":"Sarzani R, Allevi M, Di Pentima C, Schiavi P, Spannella F, Giulietti F. Role of cardiac natriuretic peptides in heart structure and function. Int J Mol Sci. 2022;23:14415. https:\/\/doi.org\/10.3390\/ijms232214415. [cited 2025 Feb 20];.","journal-title":"Int J Mol Sci"},{"key":"7821_CR83","doi-asserted-by":"publisher","unstructured":"Moubarak M, Magaud C, Saliba Y, Chatelier A, Bois P, Faivre J-F, et al. Effects of atrial natriuretic peptide on rat ventricular fibroblasts during differentiation into myofibroblasts. Physiol Res. 2015 [cited 2025 May 22];495\u2013503. https:\/\/doi.org\/10.33549\/physiolres.932839.","DOI":"10.33549\/physiolres.932839"},{"key":"7821_CR84","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms22010024","volume":"22","author":"L Mezzasoma","year":"2020","unstructured":"Mezzasoma L, Talesa VN, Romani R, Bellezza I, ANP. Exert Anti-Inflammatory action via NPR-1\/cGMP axis by interfering with Canonical, Non-Canonical, and alternative routes of inflammasome activation in human THP1 cells. Int J Mol Sci. 2020;22:24. https:\/\/doi.org\/10.3390\/ijms22010024. [cited 2025 Feb 19];.","journal-title":"Int J Mol Sci"},{"key":"7821_CR85","doi-asserted-by":"publisher","first-page":"1149717","DOI":"10.3389\/fcvm.2023.1149717","volume":"10","author":"P Silva Cunha","year":"2023","unstructured":"Silva Cunha P, Antunes DO, Laranjo S, Coutinho A, Abecasis J, Oliveira MM. Case report: mutation in NPPA gene as a cause of fibrotic atrial myopathy. Front Cardiovasc Med. 2023;10:1149717. https:\/\/doi.org\/10.3389\/fcvm.2023.1149717. [cited 2025 May 8];.","journal-title":"Front Cardiovasc Med"},{"key":"7821_CR86","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/cvr\/cvy287","volume":"115","author":"S Nattel","year":"2019","unstructured":"Nattel S. Natriuretic peptide receptors and atrial-selective fibrosis: potential role in atrial fibrillation. Cardiovasc Res. 2019;115:258\u201360. https:\/\/doi.org\/10.1093\/cvr\/cvy287. [cited 2025 May 8];.","journal-title":"Cardiovasc Res"},{"key":"7821_CR87","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/cvr\/cvt037","volume":"98","author":"MK Stokke","year":"2013","unstructured":"Stokke MK, Tovsrud N, Louch WE, \u00d8yehaug L, Hougen K, Sejersted OM, et al. I CaL Inhibition prevents arrhythmogenic Ca2\u2009+\u2009waves caused by abnormal Ca2\u2009+\u2009sensitivity of RyR or SR Ca2\u2009+\u2009accumulation. Cardiovasc Res. 2013;98:315\u201325. https:\/\/doi.org\/10.1093\/cvr\/cvt037. [cited 2025 June 17].","journal-title":"Cardiovasc Res"},{"key":"7821_CR88","doi-asserted-by":"publisher","unstructured":"Fecher C, Sodmann A, Schlott F, Jaepel J, Schmitt F, Lengfelder I et al. Resting Ca2\u2009+\u2009fluxes protect cells from fast mitochondrial fragmentation, cell stress responses, and immediate transcriptional reprogramming. Cell Mol Life Sci. 2025 [cited 2025 June 17];82:238. https:\/\/doi.org\/10.1007\/s00018-025-05745-2","DOI":"10.1007\/s00018-025-05745-2"},{"key":"7821_CR89","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/aor.12486","volume":"39","author":"Y Hellman","year":"2015","unstructured":"Hellman Y, Malik AS, Lin H, Shen C, Wang I, Wozniak TC, et al. B -Type natriuretic peptide levels predict ventricular arrhythmia post left ventricular assist device implantation. Artif Organs. 2015;39:1051\u20135. https:\/\/doi.org\/10.1111\/aor.12486. [cited 2025 May 20].","journal-title":"Artif Organs"},{"key":"7821_CR90","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCRESAHA.122.322031","volume":"132","author":"E Cachorro","year":"2023","unstructured":"Cachorro E, G\u00fcnscht M, Schubert M, Sadek MS, Siegert J, Dutt F, et al. CNP promotes antiarrhythmic effects via phosphodiesterase 2. Circ Res. 2023;132:400\u201314. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.322031. [cited 2025 May 10];.","journal-title":"Circ Res"},{"key":"7821_CR91","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M114.566695","volume":"289","author":"JI Gallea","year":"2014","unstructured":"Gallea JI, Celej MS. Structural insights into amyloid oligomers of the Parkinson Disease-related protein \u03b1-Synuclein. J Biol Chem. 2014;289:26733\u201342. https:\/\/doi.org\/10.1074\/jbc.M114.566695. [cited 2025 May 20].","journal-title":"J Biol Chem"},{"key":"7821_CR92","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.117.310738","volume":"120","author":"F Weinberger","year":"2017","unstructured":"Weinberger F, Mannhardt I, Eschenhagen T. Engineering cardiac muscle tissue: A maturating field of research. Circ Res. 2017;120:1487\u2013500. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310738. [cited 2025 May 20];.","journal-title":"Circ Res"},{"key":"7821_CR93","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1146\/annurev.ph.52.030190.003531","volume":"52","author":"ML Zeidel","year":"1990","unstructured":"Zeidel ML. Renal actions of atrial natriuretic peptide: regulation of collecting duct sodium and water transport. Annu Rev Physiol. 1990;52:747\u201359. https:\/\/doi.org\/10.1146\/annurev.ph.52.030190.003531. [cited 2025 May 22];.","journal-title":"Annu Rev Physiol"},{"key":"7821_CR94","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.ajkd.2023.06.003","volume":"82","author":"AJ Kula","year":"2023","unstructured":"Kula AJ, Bansal N. Brain natriuretic peptide monitoring in CKD: ready for prime time? Am J Kidney Dis. 2023;82:515\u20137. https:\/\/doi.org\/10.1053\/j.ajkd.2023.06.003. [cited 2025 May 8].","journal-title":"Am J Kidney Dis"},{"key":"7821_CR95","doi-asserted-by":"publisher","first-page":"16542","DOI":"10.1038\/s41598-024-67529-1","volume":"14","author":"H Hayashida","year":"2024","unstructured":"Hayashida H, Haruyama N, Fukui A, Yoshitomi R, Fujisawa H, Nakayama M. Plasma B-type natriuretic peptide is independently associated with cardiovascular events and mortality in patients with chronic kidney disease. Sci Rep. 2024;14:16542. https:\/\/doi.org\/10.1038\/s41598-024-67529-1. [cited 2025 May 8].","journal-title":"Sci Rep"},{"key":"7821_CR96","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/00029157.1976.10403798","volume":"18","author":"LK Daniels","year":"1976","unstructured":"Daniels LK. Rapid in-office and in-vivo desensitization of an injection phobia utilizing hypnosis. Am J Clin Hypn. 1976;18:200\u20133. https:\/\/doi.org\/10.1080\/00029157.1976.10403798.","journal-title":"Am J Clin Hypn"},{"key":"7821_CR97","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13054-017-1674-5","volume":"21","author":"R Haines","year":"2017","unstructured":"Haines R, Crichton S, Wilson J, Treacher D, Ostermann M. Cardiac biomarkers are associated with maximum stage of acute kidney injury in critically ill patients: a prospective analysis. Crit Care. 2017;21:88. https:\/\/doi.org\/10.1186\/s13054-017-1674-5. [cited 2025 May 8].","journal-title":"Crit Care"},{"key":"7821_CR98","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/aas.14241","volume":"67","author":"M Thol\u00e9n","year":"2023","unstructured":"Thol\u00e9n M, Kolsrud O, Dellgren G, Karason K, Lannemyr L, Ricksten S. Atrial natriuretic peptide in the prevention of acute renal dysfunction after heart transplantation\u2014a randomized placebo-controlled double\u2010blind trial. Acta Anaesthesiol Scand. 2023;67:738\u201345. https:\/\/doi.org\/10.1111\/aas.14241. [cited 2025 May 8].","journal-title":"Acta Anaesthesiol Scand"},{"key":"7821_CR99","doi-asserted-by":"publisher","first-page":"E1350","DOI":"10.1503\/cmaj.220782","volume":"194","author":"R Rumman","year":"2022","unstructured":"Rumman R, Venus K. Preoperative B-type natriuretic peptide testing in patients undergoing noncardiac surgery. Can Med Assoc J. 2022;194:E1350\u20131350. https:\/\/doi.org\/10.1503\/cmaj.220782. [cited 2025 June 16];.","journal-title":"Can Med Assoc J"},{"key":"7821_CR100","doi-asserted-by":"publisher","first-page":"96","DOI":"10.7326\/M19-2501","volume":"172","author":"E Duceppe","year":"2020","unstructured":"Duceppe E, Patel A, Chan MTV, Berwanger O, Ackland G, Kavsak PA, et al. Preoperative N -Terminal Pro\u2013B-Type natriuretic peptide and cardiovascular events after noncardiac surgery: A cohort study. Ann Intern Med. 2020;172:96\u2013104. https:\/\/doi.org\/10.7326\/M19-2501. [cited 2025 June 16].","journal-title":"Ann Intern Med"},{"key":"7821_CR101","doi-asserted-by":"publisher","unstructured":"Thompson A, Fleischmann KE, Smilowitz NR, De Las Fuentes L, Mukherjee D, Aggarwal NR, AHA\/ACC\/ACS\/ASNC\/HRS\/SCA et al. \/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery. J Am Coll Cardiol. 2024 [cited 2025 June 16];84:1869\u2013969. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.013.","DOI":"10.1016\/j.jacc.2024.06.013"},{"key":"7821_CR102","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3949\/ccjm.92a.24125","volume":"92","author":"SL Cohn","year":"2025","unstructured":"Cohn SL. 2024 ACC\/AHA guideline on perioperative cardiovascular management before noncardiac surgery: what\u2019s new? Cleve Clin J Med. 2025;92:213\u20139. https:\/\/doi.org\/10.3949\/ccjm.92a.24125. [cited 2025 June 16].","journal-title":"Cleve Clin J Med"},{"key":"7821_CR103","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1096\/fasebj.14.10.1345","volume":"14","author":"C Sengen\u00e8s","year":"2000","unstructured":"Sengen\u00e8s C, Berlan M, Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14:1345\u201351. https:\/\/doi.org\/10.1096\/fasebj.14.10.1345. [cited 2025 May 8].","journal-title":"FASEB J"},{"key":"7821_CR104","doi-asserted-by":"publisher","first-page":"eaam6870","DOI":"10.1126\/scisignal.aam6870","volume":"10","author":"W Wu","year":"2017","unstructured":"Wu W, Shi F, Liu D, Ceddia RP, Gaffin R, Wei W, et al. Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance. Sci Signal. 2017;10:eaam6870. https:\/\/doi.org\/10.1126\/scisignal.aam6870. [cited 2025 May 8];.","journal-title":"Sci Signal"},{"key":"7821_CR105","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1172\/JCI59701","volume":"122","author":"M Bordicchia","year":"2012","unstructured":"Bordicchia M, Liu D, Amri E-Z, Ailhaud G, Dess\u00ec-Fulgheri P, Zhang C, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122:1022\u201336. https:\/\/doi.org\/10.1172\/JCI59701. [cited 2025 May 8];.","journal-title":"J Clin Invest"},{"key":"7821_CR106","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41598-018-19619-0","volume":"8","author":"M Cou\u00e9","year":"2018","unstructured":"Cou\u00e9 M, Barquissau V, Morigny P, Louche K, Lefort C, Mairal A, et al. Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes. Sci Rep. 2018;8:1097. https:\/\/doi.org\/10.1038\/s41598-018-19619-0. [cited 2025 May 8];.","journal-title":"Sci Rep"},{"key":"7821_CR107","doi-asserted-by":"publisher","unstructured":"Jordan J, Birkenfeld AL, Melander O, Moro C. Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk: Implications for Hypertension Management. Hypertension. 2018 [cited 2025 May 8];72:270\u20136. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11081","DOI":"10.1161\/HYPERTENSIONAHA.118.11081"},{"key":"7821_CR108","doi-asserted-by":"publisher","first-page":"674254","DOI":"10.3389\/fphys.2021.674254","volume":"12","author":"EEA Egom","year":"2021","unstructured":"Egom EEA. Natriuretic peptide clearance receptor (NPR-C) pathway as a novel therapeutic target in Obesity-Related heart failure with preserved ejection fraction (HFpEF). Front Physiol. 2021;12:674254. https:\/\/doi.org\/10.3389\/fphys.2021.674254. [cited 2025 May 8];.","journal-title":"Front Physiol"},{"key":"7821_CR109","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/oby.21418","volume":"24","author":"Z Kovacova","year":"2016","unstructured":"Kovacova Z, Tharp WG, Liu D, Wei W, Xie H, Collins S, et al. Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. Obesity. 2016;24:820\u20138. https:\/\/doi.org\/10.1002\/oby.21418. [cited 2025 May 8].","journal-title":"Obesity"},{"key":"7821_CR110","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/clinem\/dgae450","volume":"110","author":"JS Nam","year":"2025","unstructured":"Nam JS, Cho E-S, Kwon YR, Park JS, Kim Y. Dynamic response of Musclin, a Myokine, to aerobic exercise and its interplay with natriuretic peptides and receptor C. J Clin Endocrinol Metab. 2025;110:1305\u201314. https:\/\/doi.org\/10.1210\/clinem\/dgae450. [cited 2025 May 8].","journal-title":"J Clin Endocrinol Metab"},{"key":"7821_CR111","doi-asserted-by":"publisher","first-page":"1095432","DOI":"10.3389\/fendo.2023.1095432","volume":"14","author":"R Zhu","year":"2023","unstructured":"Zhu R, Chen S. Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice. Front Endocrinol. 2023;14:1095432. https:\/\/doi.org\/10.3389\/fendo.2023.1095432. [cited 2025 May 19];.","journal-title":"Front Endocrinol"},{"key":"7821_CR112","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1111\/dom.16294","volume":"27","author":"A Zhang","year":"2025","unstructured":"Zhang A, Liu Q, Xiong Y, Li J, Xu Y, Song H, et al. Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice. Diabetes Obes Metab. 2025;27:2844\u201356. https:\/\/doi.org\/10.1111\/dom.16294. [cited 2025 May 19];.","journal-title":"Diabetes Obes Metab"},{"key":"7821_CR113","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037\u201348. https:\/\/doi.org\/10.1038\/s41591-024-03018-2. [cited 2025 May 19];.","journal-title":"Nat Med"},{"key":"7821_CR114","doi-asserted-by":"publisher","unstructured":"Vila G, Resl M, Stelzeneder D, Struck J, Maier C, Riedl M et al. Plasma NT-proBNP increases in response to LPS administration in healthy men. J Appl Physiol. 2008 [cited 2025 May 19];105:1741\u20135. https:\/\/doi.org\/10.1152\/japplphysiol.90442.2008","DOI":"10.1152\/japplphysiol.90442.2008"},{"key":"7821_CR115","doi-asserted-by":"publisher","first-page":"10999","DOI":"10.1038\/s41598-024-61888-5","volume":"14","author":"Y Choi","year":"2024","unstructured":"Choi Y, Lee JH. Clinical usefulness of NT-proBNP as a prognostic factor for septic shock patients presenting to the emergency department. Sci Rep. 2024;14:10999. https:\/\/doi.org\/10.1038\/s41598-024-61888-5. [cited 2025 May 19];.","journal-title":"Sci Rep"},{"key":"7821_CR116","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/annrheumdis-2012-202848","volume":"73","author":"H Mirjafari","year":"2014","unstructured":"Mirjafari H, Welsh P, Verstappen SMM, Wilson P, Marshall T, Edlin H, et al. N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk arthritis registry (NOAR). Ann Rheum Dis. 2014;73:684. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202848.","journal-title":"Ann Rheum Dis"},{"key":"7821_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/962347","volume":"2012","author":"T Ogawa","year":"2012","unstructured":"Ogawa T, De Bold AJ. Brain natriuretic peptide production and secretion in inflammation. J Transpl. 2012;2012:1\u20137. https:\/\/doi.org\/10.1155\/2012\/962347. [cited 2025 May 8];.","journal-title":"J Transpl"},{"key":"7821_CR118","doi-asserted-by":"publisher","unstructured":"Goldenberg D, Miller E, Perna M, Sattar N, Welsh P, Roman MJ et al. Association of N-terminal pro\u2013brain natriuretic peptide with cardiac disease, but not with vascular disease, in systemic lupus erythematosus. Arthritis Rheum. 2012 [cited 2025 May 8];64:316\u20137. https:\/\/doi.org\/10.1002\/art.33374","DOI":"10.1002\/art.33374"},{"key":"7821_CR119","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.atherosclerosis.2016.10.016","volume":"254","author":"P Welsh","year":"2016","unstructured":"Welsh P, Tuckwell K, McInnes IB, Sattar N. Effect of IL-6 receptor Blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis. 2016;254:167\u201371. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.10.016. [cited 2025 May 8].","journal-title":"Atherosclerosis"},{"key":"7821_CR120","doi-asserted-by":"publisher","unstructured":"Peters MJL, Welsh P, McInnes IB, Wolbink G, Dijkmans BAC, Sattar N et al. Tumour necrosis factor \u03b1 blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis. 2010 [cited 2025 May 8];69:1281\u20135. https:\/\/doi.org\/10.1136\/ard.2009.119412","DOI":"10.1136\/ard.2009.119412"},{"key":"7821_CR121","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/ejhf.1138","volume":"20","author":"S Frantz","year":"2018","unstructured":"Frantz S, Falcao-Pires I, Balligand J, Bauersachs J, Brutsaert D, Ciccarelli M, et al. The innate immune system in chronic cardiomyopathy: a European society of cardiology (ESC) scientific statement from the working group on myocardial function of the ESC. Eur J Heart Fail. 2018;20:445\u201359. https:\/\/doi.org\/10.1002\/ejhf.1138. [cited 2025 May 8];.","journal-title":"Eur J Heart Fail"},{"key":"7821_CR122","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.4049\/jimmunol.170.12.5869","volume":"170","author":"R Morita","year":"2003","unstructured":"Morita R, Ukyo N, Furuya M, Uchiyama T, Hori T. Atrial natriuretic peptide polarizes human dendritic cells toward a Th2-Promoting phenotype through its receptor Guanylyl Cyclase-Coupled receptor A. J Immunol. 2003;170:5869\u201375. https:\/\/doi.org\/10.4049\/jimmunol.170.12.5869. [cited 2025 May 8].","journal-title":"J Immunol"},{"key":"7821_CR123","first-page":"235","volume":"48","author":"JC Burnett","year":"2006","unstructured":"Burnett JC. Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what\u2019s on the horizon. J Cardiol. 2006;48:235\u201341.","journal-title":"J Cardiol"},{"key":"7821_CR124","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCHEARTFAILURE.108.776294","volume":"1","author":"JC Burnett","year":"2008","unstructured":"Burnett JC, Korinek J. The tumultuous journey of nesiritide: Past, Present, and future. Circ Heart Fail. 2008;1:6\u20138. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.108.776294. [cited 2025 May 11];.","journal-title":"Circ Heart Fail"},{"key":"7821_CR125","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1189\/jlb.0603254","volume":"74","author":"NC Weber","year":"2003","unstructured":"Weber NC, Blumenthal SB, Hartung T, Vollmar AM, Kiemer AK. ANP inhibits TNF-\u03b1-induced endothelial MCP-1 expression\u2014involvement of p38 MAPK and MKP-1. J Leukoc Biol. 2003;74:932\u201341. https:\/\/doi.org\/10.1189\/jlb.0603254. [cited 2025 May 8].","journal-title":"J Leukoc Biol"},{"key":"7821_CR126","doi-asserted-by":"publisher","unstructured":"Packer M, Kitzman DW. Obesity-Related Heart Failure With a Preserved Ejection Fraction. JACC Heart Fail. 2018 [cited 2025 May 8];6:633\u20139. https:\/\/doi.org\/10.1016\/j.jchf.2018.01.009","DOI":"10.1016\/j.jchf.2018.01.009"},{"key":"7821_CR127","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.3390\/ijms20092281","volume":"20","author":"AJ Moyes","year":"2019","unstructured":"Moyes AJ, Hobbs AJ, C-Type Natriuretic. Peptide: A multifaceted paracrine regulator in the heart and vasculature. Int J Mol Sci. 2019;20:2281. https:\/\/doi.org\/10.3390\/ijms20092281. [cited 2025 May 11];.","journal-title":"Int J Mol Sci"},{"key":"7821_CR128","doi-asserted-by":"publisher","first-page":"681726","DOI":"10.3389\/fcvm.2021.681726","volume":"8","author":"P Huang","year":"2021","unstructured":"Huang P, Guo Z, Liang W, Wu Y, Zhao J, He X, et al. Weight change and mortality risk in heart failure with preserved ejection fraction. Front Cardiovasc Med. 2021;8:681726. https:\/\/doi.org\/10.3389\/fcvm.2021.681726. [cited 2025 May 20];.","journal-title":"Front Cardiovasc Med"},{"key":"7821_CR129","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14336\/AD.2022.0523","volume":"14","author":"Z Cai","year":"2023","unstructured":"Cai Z, Wu C, Xu Y, Cai J, Zhao M, Zu L. The NO-cGMP-PKG axis in hfpef: from pathological mechanisms to potential therapies. Aging Dis. 2023;14:46. https:\/\/doi.org\/10.14336\/AD.2022.0523. [cited 2025 May 8];.","journal-title":"Aging Dis"},{"key":"7821_CR130","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi","year":"2019","unstructured":"Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in N-Terminal Pro\u2013B-Type natriuretic peptide following initiation of Sacubitril-Valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322:1085. https:\/\/doi.org\/10.1001\/jama.2019.12821. [cited 2025 May 8];.","journal-title":"JAMA"},{"key":"7821_CR131","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijcard.2018.06.002","volume":"281","author":"T Ichiki","year":"2019","unstructured":"Ichiki T, Dzhoyashvili N, Burnett JC. Natriuretic peptide based therapeutics for heart failure: cenderitide: A novel first-in-class designer natriuretic peptide. Int J Cardiol. 2019;281:166\u201371. https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.002. [cited 2025 May 11].","journal-title":"Int J Cardiol"},{"key":"7821_CR132","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/cpt.974","volume":"104","author":"R Kawakami","year":"2018","unstructured":"Kawakami R, Lee CYW, Scott C, Bailey KR, Schirger JA, Chen HH, et al. A human study to evaluate Safety, Tolerability, and Cyclic GMP activating properties of Cenderitide in subjects with stable chronic heart failure. Clin Pharmacol Ther. 2018;104:546\u201352. https:\/\/doi.org\/10.1002\/cpt.974. [cited 2025 May 11];.","journal-title":"Clin Pharmacol Ther"},{"key":"7821_CR133","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jacbts.2016.10.001","volume":"1","author":"LMG Meems","year":"2016","unstructured":"Meems LMG, Burnett JC. Innovative therapeutics. JACC Basic Transl Sci. 2016;1:557\u201367. https:\/\/doi.org\/10.1016\/j.jacbts.2016.10.001. cited 2025 May 8.","journal-title":"JACC Basic Transl Sci"},{"key":"7821_CR134","doi-asserted-by":"publisher","first-page":"R407","DOI":"10.1152\/ajpregu.00286.2017","volume":"314","author":"Y Chen","year":"2018","unstructured":"Chen Y, Harty GJ, Huntley BK, Iyer SR, Heublein DM, Harders GE, et al. CRRL269: a novel designer and renal-enhancing pGC-A peptide activator. Am J Physiol-Regul Integr Comp Physiol. 2018;314:R407\u201314. https:\/\/doi.org\/10.1152\/ajpregu.00286.2017. [cited 2025 May 11];.","journal-title":"Am J Physiol-Regul Integr Comp Physiol"},{"key":"7821_CR135","doi-asserted-by":"publisher","unstructured":"Meems LMG, Andersen IA, Pan S, Harty G, Chen Y, Zheng Y et al. Design, Synthesis, and actions of an innovative bispecific designer peptide: NPA7. Hypertension. 2019 [cited 2025 May 20];73:900\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.12012","DOI":"10.1161\/HYPERTENSIONAHA.118.12012"},{"key":"7821_CR136","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/HYPERTENSIONAHA.124.23579","volume":"82","author":"X Ma","year":"2025","unstructured":"Ma X, Malsawmzuali JC, Moroni DG, Ma X, Zheng Y, Pan S, et al. NPA7: A dual receptor activating peptide that inhibits cardiac oxidative stress. Hypertension. 2025;82:463\u201375. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.23579. [cited 2025 May 8];.","journal-title":"Hypertension"},{"key":"7821_CR137","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.yjmcc.2019.03.024","volume":"130","author":"Y Chen","year":"2019","unstructured":"Chen Y, Zheng Y, Iyer SR, Harders GE, Pan S, Chen HH, et al. C53: A novel particulate Guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. J Mol Cell Cardiol. 2019;130:140\u201350. https:\/\/doi.org\/10.1016\/j.yjmcc.2019.03.024. [cited 2025 May 20].","journal-title":"J Mol Cell Cardiol"},{"key":"7821_CR138","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.yjmcc.2019.03.015","volume":"130","author":"J Fassett","year":"2019","unstructured":"Fassett J, Xu X, Kwak D, Zhu G, Fassett EK, Zhang P, et al. Adenosine kinase attenuates cardiomyocyte microtubule stabilization and protects against pressure overload-induced hypertrophy and LV dysfunction. J Mol Cell Cardiol. 2019;130:49\u201358. https:\/\/doi.org\/10.1016\/j.yjmcc.2019.03.015. [cited 2025 May 8];.","journal-title":"J Mol Cell Cardiol"},{"key":"7821_CR139","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bbrc.2021.03.028","volume":"552","author":"M Nishida","year":"2021","unstructured":"Nishida M, Miyamoto K, Abe S, Shimada M, Shimizu Y, Tsuji A, et al. Natriuretic peptide receptor-C releases and activates guanine nucleotide-exchange factor H1 in a ligand-dependent manner. Biochem Biophys Res Commun. 2021;552:9\u201316. https:\/\/doi.org\/10.1016\/j.bbrc.2021.03.028. [cited 2025 May 20];.","journal-title":"Biochem Biophys Res Commun"},{"key":"7821_CR140","doi-asserted-by":"publisher","first-page":"e2109386118","DOI":"10.1073\/pnas.2109386118","volume":"118","author":"SJ Sangaralingham","year":"2021","unstructured":"Sangaralingham SJ, Whig K, Peddibhotla S, Kirby RJ, Sessions HE, Maloney PR, et al. Discovery of small molecule Guanylyl cyclase A receptor positive allosteric modulators. Proc Natl Acad Sci. 2021;118:e2109386118. https:\/\/doi.org\/10.1073\/pnas.2109386118. [cited 2025 May 8].","journal-title":"Proc Natl Acad Sci"},{"key":"7821_CR141","doi-asserted-by":"publisher","first-page":"9642","DOI":"10.3390\/ijms24119642","volume":"24","author":"V Della Corte","year":"2023","unstructured":"Della Corte V, Pacinella G, Todaro F, Pecoraro R, Tuttolomondo A. The natriuretic peptide system: A single Entity, pleiotropic effects. Int J Mol Sci. 2023;24:9642. https:\/\/doi.org\/10.3390\/ijms24119642. [cited 2025 May 8];.","journal-title":"Int J Mol Sci"},{"key":"7821_CR142","doi-asserted-by":"publisher","unstructured":"Tonne JM, Holditch SJ, Oehler EA, Schreiber CA, Ikeda Y, Cataliotti A. Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease. Aging. 2014 [cited 2025 May 11];6:311\u20139. https:\/\/doi.org\/10.18632\/aging.100655","DOI":"10.18632\/aging.100655"},{"key":"7821_CR143","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/01.HYP.33.1.219","volume":"33","author":"K-F Lin","year":"1999","unstructured":"Lin K-F, Chao J, Chao L. Atrial natriuretic peptide gene delivery reduces Stroke-Induced mortality rate in Dahl Salt-Sensitive rats. Hypertension. 1999;33:219\u201324. https:\/\/doi.org\/10.1161\/01.HYP.33.1.219. [cited 2025 May 11];.","journal-title":"Hypertension"},{"key":"7821_CR144","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1038\/s41598-019-42592-1","volume":"9","author":"M Lawless","year":"2019","unstructured":"Lawless M, Caldwell JL, Radcliffe EJ, Smith CER, Madders GWP, Hutchings DC, et al. Phosphodiesterase 5 Inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure. Sci Rep. 2019;9:6801. https:\/\/doi.org\/10.1038\/s41598-019-42592-1. [cited 2025 May 20];.","journal-title":"Sci Rep"},{"key":"7821_CR145","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"MM Redfield","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of Phosphodiesterase-5 Inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA. 2013;309:1268. https:\/\/doi.org\/10.1001\/jama.2013.2024. [cited 2025 May 20].","journal-title":"JAMA"},{"key":"7821_CR146","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCHEARTFAILURE.110.944694","volume":"4","author":"M Guazzi","year":"2011","unstructured":"Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 Inhibition with sildenafil improves left ventricular diastolic Function, cardiac Geometry, and clinical status in patients with stable systolic heart failure: results of a 1-Year, Prospective, Randomized, Placebo-Controlled study. Circ Heart Fail. 2011;4:8\u201317. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.110.944694. [cited 2025 May 20].","journal-title":"Circ Heart Fail"},{"key":"7821_CR147","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.regpep.2008.02.009","volume":"148","author":"V Chiurchi\u00f9","year":"2008","unstructured":"Chiurchi\u00f9 V, Izzi V, D\u2019Aquilio F, Carotenuto F, Di Nardo P, Baldini PM. Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept. 2008;148:26\u201332. https:\/\/doi.org\/10.1016\/j.regpep.2008.02.009. [cited 2025 May 8].","journal-title":"Regul Pept"},{"key":"7821_CR148","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin\u2013Neprilysin Inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1812851. [cited 2025 May 8].","journal-title":"N Engl J Med"},{"key":"7821_CR149","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.2017.10565","volume":"318","author":"GM Felker","year":"2017","unstructured":"Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of natriuretic Peptide\u2013Guided therapy on hospitalization or cardiovascular mortality in High-Risk patients with heart failure and reduced ejection fraction: A randomized clinical trial. JAMA. 2017;318:713. https:\/\/doi.org\/10.1001\/jama.2017.10565. [cited 2025 May 8];.","journal-title":"JAMA"},{"key":"7821_CR150","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2018;72:351\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070. [cited 2025 May 8].","journal-title":"J Am Coll Cardiol"},{"key":"7821_CR151","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ejhf.286","volume":"17","author":"MT Ledwidge","year":"2015","unstructured":"Ledwidge MT, O\u2019Connell E, Gallagher J, Tilson L, James S, Voon V, et al. Cost-effectiveness of natriuretic peptide\u2010based screening and collaborative care: a report from the STOP\u2010HF (St vincent\u2019s screening TO prevent heart Failure) study. Eur J Heart Fail. 2015;17:672\u20139. https:\/\/doi.org\/10.1002\/ejhf.286. [cited 2025 May 8].","journal-title":"Eur J Heart Fail"},{"key":"7821_CR152","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013Neprilysin Inhibition versus Enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077. [cited 2025 May 8].","journal-title":"N Engl J Med"},{"key":"7821_CR153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","author":"Velazquez","year":"2018","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin\u2013Neprilysin Inhibition in acute decompensated heart failure. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1812851. cited 2018 Nov 14.","journal-title":"N Engl J Med"},{"key":"7821_CR154","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.1498","volume":"21","author":"R Wachter","year":"2019","unstructured":"Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, et al. Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21:998\u20131007. https:\/\/doi.org\/10.1002\/ejhf.1498. [cited 2025 May 22].","journal-title":"Eur J Heart Fail"},{"key":"7821_CR155","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1111\/jgs.16717","volume":"68","author":"TM Liew","year":"2020","unstructured":"Liew TM, Tai BC, Wee SL, Koh GC, Yap P. The longitudinal effects of caregiver grief in dementia and the modifying effects of social services: A prospective cohort study. J Am Geriatr Soc. 2020;68:2348\u201353. https:\/\/doi.org\/10.1111\/jgs.16717. [cited 2025 May 22].","journal-title":"J Am Geriatr Soc"},{"key":"7821_CR156","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, et al. Effects of Sacubitril\/Valsartan versus Irbesartan in patients with chronic kidney disease: A randomized Double-Blind trial. Circulation. 2018;138:1505\u201314. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034818. [cited 2025 May 22].","journal-title":"Circulation"},{"key":"7821_CR157","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/jama.2017.10567","volume":"318","author":"AM Valent","year":"2017","unstructured":"Valent AM, DeArmond C, Houston JM, Reddy S, Masters HR, Gold A, et al. Effect of Post\u2013Cesarean delivery oral cephalexin and metronidazole on surgical site infection among obese women: A randomized clinical trial. JAMA. 2017;318:1026. https:\/\/doi.org\/10.1001\/jama.2017.10567. [cited 2025 May 22];.","journal-title":"JAMA"},{"key":"7821_CR158","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391:1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107. [cited 2025 May 22].","journal-title":"N Engl J Med"},{"key":"7821_CR159","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2030183. [cited 2025 May 8].","journal-title":"N Engl J Med"},{"key":"7821_CR160","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jacbts.2018.08.004","volume":"3","author":"M Mackasey","year":"2018","unstructured":"Mackasey M, Egom EE, Jansen HJ, Hua R, Moghtadaei M, Liu Y, et al. Natriuretic peptide Receptor-C protects against angiotensin II-Mediated sinoatrial node disease in mice. JACC Basic Transl Sci. 2018;3:824\u201343. https:\/\/doi.org\/10.1016\/j.jacbts.2018.08.004. [cited 2025 May 11].","journal-title":"JACC Basic Transl Sci"},{"key":"7821_CR161","doi-asserted-by":"publisher","unstructured":"Hobbs AJ. Natriuretic peptide receptors and heart failure: to B or not to B blocked? Naunyn schmiedebergs arch Pharmacol. 2014 [cited 2025 May 11];387:1\u20134. https:\/\/doi.org\/10.1007\/s00210-013-0946-0","DOI":"10.1007\/s00210-013-0946-0"},{"key":"7821_CR162","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.118.036344","volume":"139","author":"KJ Bubb","year":"2019","unstructured":"Bubb KJ, Aubdool AA, Moyes AJ, Lewis S, Drayton JP, Tang O, et al. Endothelial C-Type natriuretic peptide is a critical regulator of angiogenesis and vascular remodeling. Circulation. 2019;139:1612\u201328. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036344.","journal-title":"Circulation"},{"key":"7821_CR163","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/eurheartj\/ehz093","volume":"41","author":"AJ Moyes","year":"2020","unstructured":"Moyes AJ, Chu SM, Aubdool AA, Dukinfield MS, Margulies KB, Bedi KC, et al. C-type natriuretic peptide co-ordinates cardiac structure and function. Eur Heart J. 2020;41:1006\u201320. https:\/\/doi.org\/10.1093\/eurheartj\/ehz093. [cited 2025 Feb 20].","journal-title":"Eur Heart J"},{"key":"7821_CR164","doi-asserted-by":"publisher","unstructured":"Cada DJ, Baker DE, Leonard J, Sacubitril\/Valsartan. Hosp Pharm. 2015 [cited 2025 May 11];50:1025\u201336. https:\/\/doi.org\/10.1310\/hpj5011-1025","DOI":"10.1310\/hpj5011-1025"},{"key":"7821_CR165","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Gali\u00e8","year":"2005","unstructured":"Gali\u00e8 N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148\u201357. https:\/\/doi.org\/10.1056\/NEJMoa050010. [cited 2025 May 11].","journal-title":"N Engl J Med"},{"key":"7821_CR166","doi-asserted-by":"publisher","first-page":"e031796","DOI":"10.1161\/JAHA.123.031796","volume":"13","author":"L Chiu","year":"2024","unstructured":"Chiu L, Agrawal V, Armstrong D, Brittain E, Collins S, Hemnes AR, et al. Correlates of plasma NT-proBNP\/Cyclic GMP ratio in heart failure with preserved ejection fraction: an analysis of the RELAX trial. J Am Heart Assoc. 2024;13:e031796. https:\/\/doi.org\/10.1161\/JAHA.123.031796. [cited 2025 May 11];.","journal-title":"J Am Heart Assoc"},{"key":"7821_CR167","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.123.066605","volume":"150","author":"R Shaddy","year":"2024","unstructured":"Shaddy R, Burch M, Kantor PF, Solar-Yohay S, Garito T, Zhang S, et al. Sacubitril\/Valsartan in pediatric heart failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind trial. Circulation. 2024;150:1756\u201366. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066605. [cited 2025 May 11].","journal-title":"Circulation"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07821-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:07:49Z","timestamp":1784624869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07821-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":167,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7821"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07821-y","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"17 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this review article, as it did not involve human or animal subjects.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest or competing interests relevant to the content of this article.","order":4,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}